Scoop has an Ethical Paywall
Merck Statement on COX-2 Inhibitors
Friday 29 April 2005
Alister Brown, managing director of Merck Sharp & Dohme New Zealand (MSD NZ), made the following comments in response to today’s announcement by the Ministry of Health that COX-2 inhibitors will remain available in New Zealand:
“At this time, Medsafe has issued new prescribing advice for selective Cox-2 inhibitor medicines, including ARCOXIA® (etoricoxib).
“We welcome the decision by Medsafe that will allow ARCOXIA to remain as a prescribing option in New Zealand. We are reviewing the actions of Medsafe and look forward to our discussions with the agency with respect to ARCOXIA.
“MSD NZ is continuing studies to further establish the long-term cardiovascular and overall safety profile of ARCOXIA.”
ENDS
Advertisement - scroll to continue reading
New Zealand College of Midwives: Celebrating Midwives Across Aotearoa This International Day Of The Midwife
PPTA Te Wehengarua: Building The Secondary Curriculum On Broken Drafts Is A Serious Risk
Whanganui Regional Museum: Whanganui Makers Bring Textile Traditions To Life During Symposium Weekend
Palmerston North Hospital Foundation: Fundraising For Publicly-Owned Surgical Robot Hits $2 Million Milestone In Less Than Three Months
Otago Shore And Land Trust: Hīkoi O Te Taoka - Larger Than Life Hoiho Statues Go To Auction For Charity
Tertiary Education Union: Historic MECA Negotiations In Polytechnic Sector Begin